151 related articles for article (PubMed ID: 18344807)
1. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
Terrier B; Jaccard A; Harousseau JL; Delarue R; Tournilhac O; Hunault-Berger M; Hamidou M; Dantal J; Bernard M; Grosbois B; Morel P; Coiteux V; Gisserot O; Rodon P; Hot A; Elie C; Leblond V; Fermand JP; Fakhouri F
Medicine (Baltimore); 2008 Mar; 87(2):99-109. PubMed ID: 18344807
[TBL] [Abstract][Full Text] [Related]
2. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
3. Clinical presentation and treatment responses in IgM-related AL amyloidosis.
Sissoko M; Sanchorawala V; Seldin D; Sworder B; Angelino K; Broce M; Berk J; Sloan JM
Amyloid; 2015; 22(4):229-35. PubMed ID: 26488936
[TBL] [Abstract][Full Text] [Related]
4. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients.
Chauvet S; Bridoux F; Ecotière L; Javaugue V; Sirac C; Arnulf B; Thierry A; Quellard N; Milin S; Bender S; Goujon JM; Jaccard A; Fermand JP; Touchard G
Am J Kidney Dis; 2015 Nov; 66(5):756-67. PubMed ID: 25987261
[TBL] [Abstract][Full Text] [Related]
5. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation and IgM amyloidosis.
Valente M; Roy V; Lacy MQ; Dispenzieri A; Gertz MA
Leuk Lymphoma; 2006 Jun; 47(6):1006-12. PubMed ID: 16840189
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; Lokhorst HL; van der Pol WL; Franssen H; Wokke JH; Notermans NC
J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1036-9. PubMed ID: 19684235
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
[TBL] [Abstract][Full Text] [Related]
9. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
Wechalekar AD; Lachmann HJ; Goodman HJ; Bradwell A; Hawkins PN; Gillmore JD
Blood; 2008 Nov; 112(10):4009-16. PubMed ID: 18708629
[TBL] [Abstract][Full Text] [Related]
10. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal IgM-related AL amyloidosis.
Milani P; Merlini G
Best Pract Res Clin Haematol; 2016 Jun; 29(2):241-248. PubMed ID: 27825470
[TBL] [Abstract][Full Text] [Related]
12. Amyloidosis with IgM monoclonal gammopathies.
Gertz MA; Kyle RA
Semin Oncol; 2003 Apr; 30(2):325-8. PubMed ID: 12720162
[TBL] [Abstract][Full Text] [Related]
13. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
Amyloid; 2009; 16(3):183-5. PubMed ID: 19590992
[TBL] [Abstract][Full Text] [Related]
14. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
Le Cann M; Bouhour F; Viala K; Simon L; Tard C; Rossi C; Morel G; Lagrange E; Magy L; Créange A; Michaud M; Franques J; Echaniz-Laguna A; Antoine JC; Baron M; Arnulf B; Puma A; Delmont E; Maisonobe T; Leblond V; Roos-Weil D
Blood; 2020 Nov; 136(21):2428-2436. PubMed ID: 32959046
[TBL] [Abstract][Full Text] [Related]
15. Transplantation for IgM amyloidosis and IgM myeloma.
Gertz MA; Hayman SR; Buadi FK
Clin Lymphoma Myeloma; 2009 Mar; 9(1):77-9. PubMed ID: 19362980
[TBL] [Abstract][Full Text] [Related]
16. IgM amyloidosis: clinical features in therapeutic outcomes.
Gertz MA; Buadi FK; Hayman SR
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):146-8. PubMed ID: 21454218
[TBL] [Abstract][Full Text] [Related]
17. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
18. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
[TBL] [Abstract][Full Text] [Related]
19. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
Palladini G; Russo P; Bosoni T; Sarais G; Lavatelli F; Foli A; Bragotti LZ; Perfetti V; Obici L; Bergesio F; Albertini R; Moratti R; Merlini G
Clin Lymphoma Myeloma; 2009 Mar; 9(1):80-3. PubMed ID: 19362981
[TBL] [Abstract][Full Text] [Related]
20. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.
Gertz MA; Kyle RA; Noel P
J Clin Oncol; 1993 May; 11(5):914-20. PubMed ID: 8487054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
